SCHEMBL2933842

SCHEMBL2933842

Nc1ncc(-c2ccc(C(=O)N3CCOCC3)cc2F)nc1-c1cc2ccccc2[nH]1

nearest known ligand 0.56

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
ATR Q13535 10/20 0.56
ALOX5AP P20292 3/20 0.51
FEN1 P39748 3/20 0.51
KCNH2 Q12809 1/20 0.47
POLB P06746 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
PRKDC P78527 1/20 0.45
ATM Q13315 1/20 0.45
RIPK1 Q13546 1/20 0.44
KDR P35968 1/20 0.42
JAK2 O60674 1/20 0.42
LRRK2 Q5S007 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2927601 0.90 KDR (0.54) ATRKCNH2PRKDCATMRIPK1
SCHEMBL2932607 0.88 ATR (0.63) ATRKCNH2PRKDCATMRIPK1
SCHEMBL2927054 0.86 POLB (0.49) ATRALOX5APFEN1POLBSMN1; SMN2
SCHEMBL2932858 0.80 KCNH2 (0.58) ATRALOX5APFEN1KCNH2LRRK2
SCHEMBL2927597 0.75 KDR (0.58) RIPK1KDRJAK2
SCHEMBL2931317 0.72 MKNK1 (0.52) ATRALOX5APFEN1KCNH2
SCHEMBL29458584 0.72 ATR (1.00) ATR
SCHEMBL3063607 0.72 ATR (1.00) ATR
SCHEMBL2927882 0.71 RIPK1 (0.55) ATRPOLBSMN1; SMN2RIPK1KDR
SCHEMBL2928618 0.71 KDM4E (0.52) ATRPOLBSMN1; SMN2RIPK1KDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2044051-B1 PYRIDINE AND PYRAZINE DERIVATIVES AS MNK KINASE INHIBITORS BIOVITRUM AB PUBL (SE) 2010-01-27 EP claimed
EP-2044051-A1 PYRIDINE AND PYRAZINE DERIVATIVES AS MNK KINASE INHIBITORS BIOVITRUM AB (publ) (SE) 2009-04-08 EP claimed
US-20080039450-A1 Compounds BIOVITRUM AB (PUBL.) (SE) 2008-02-14 US claimed
WO-2007147874-A1 PYRIDINE AND PYRAZINE DERIVATIVES AS MNK KINASE INHIBITORS BIOVITRUM AB (PUBL) (SE) 2007-12-27 WO claimed
EP-2044051-B1 PYRIDINE AND PYRAZINE DERIVATIVES AS MNK KINASE INHIBITORS BIOVITRUM AB PUBL (SE) 2010-01-27 EP disclosed
EP-2044051-B1 PYRIDINE AND PYRAZINE DERIVATIVES AS MNK KINASE INHIBITORS BIOVITRUM AB PUBL (SE) 2010-01-27 EP disclosed
US-20080039450-A1 Compounds BIOVITRUM AB (PUBL.) (SE) 2008-02-14 US disclosed
US-20080039450-A1 Compounds BIOVITRUM AB (PUBL.) (SE) 2008-02-14 US disclosed
US-20080039450-A1 Compounds BIOVITRUM AB (PUBL.) (SE) 2008-02-14 US disclosed
WO-2007147874-A1 PYRIDINE AND PYRAZINE DERIVATIVES AS MNK KINASE INHIBITORS BIOVITRUM AB (PUBL) (SE) 2007-12-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080039450-A1 Compounds NEK2, CSNK2A3, CSNK2A1 ATR 556/4885ALOX5AP 4094/4885FEN1 1864/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.